{"data":{"id":"10.6084/m9.figshare.3381292","type":"dois","attributes":{"doi":"10.6084/m9.figshare.3381292","prefix":"10.6084","suffix":"m9.figshare.3381292","identifiers":[],"alternateIdentifiers":[],"creators":[{"name":"Akhilesh  Gupta","affiliation":[],"nameIdentifiers":[]}],"titles":[{"title":"An analytical approach of doxofylline: review"}],"publisher":"figshare","container":{},"publicationYear":2016,"subjects":[{"subject":"60101 Analytical Biochemistry","subjectScheme":"FOR"},{"subject":"FOS: Biological sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Biological sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"30199 Analytical Chemistry not elsewhere classified","subjectScheme":"FOR"},{"subject":"FOS: Chemical sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Chemical sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"30101 Analytical Spectrometry","subjectScheme":"FOR"},{"subject":"110701 Allergy","subjectScheme":"FOR"},{"subject":"FOS: Clinical medicine","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Clinical medicine","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"111501 Basic Pharmacology","subjectScheme":"FOR"},{"subject":"111205 Chemotherapy","subjectScheme":"FOR"},{"subject":"111101 Clinical and Sports Nutrition","subjectScheme":"FOR"},{"subject":"FOS: Health sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Health sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"110302 Clinical Chemistry (diagnostics)","subjectScheme":"FOR"},{"subject":"110303 Clinical Microbiology","subjectScheme":"FOR"},{"subject":"111002 Clinical Nursing: Primary (Preventative)","subjectScheme":"FOR"},{"subject":"111003 Clinical Nursing: Secondary (Acute Care)","subjectScheme":"FOR"},{"subject":"111004 Clinical Nursing: Tertiary (Rehabilitative)","subjectScheme":"FOR"},{"subject":"111502 Clinical Pharmacology and Therapeutics","subjectScheme":"FOR"},{"subject":"111503 Clinical Pharmacy and Pharmacy Practice","subjectScheme":"FOR"},{"subject":"110399 Clinical Sciences not elsewhere classified","subjectScheme":"FOR"},{"subject":"111704 Community Child Health","subjectScheme":"FOR"},{"subject":"110305 Emergency Medicine","subjectScheme":"FOR"},{"subject":"111705 Environmental and Occupational Health and Safety","subjectScheme":"FOR"},{"subject":"111706 Epidemiology","subjectScheme":"FOR"},{"subject":"111707 Family Care","subjectScheme":"FOR"},{"subject":"111708 Health and Community Services","subjectScheme":"FOR"},{"subject":"Health Care"},{"subject":"111709 Health Care Administration","subjectScheme":"FOR"},{"subject":"111710 Health Counselling","subjectScheme":"FOR"},{"subject":"111711 Health Information Systems (incl. Surveillance)","subjectScheme":"FOR"},{"subject":"111712 Health Promotion","subjectScheme":"FOR"},{"subject":"111602 Human Biophysics","subjectScheme":"FOR"},{"subject":"FOS: Basic medicine","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Basic medicine","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"110699 Human Movement and Sports Science not elsewhere classified","subjectScheme":"FOR"},{"subject":"110310 Intensive Care","subjectScheme":"FOR"},{"subject":"119999 Medical and Health Sciences not elsewhere classified","subjectScheme":"FOR"},{"subject":"FOS: Other medical sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Other medical sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"110801 Medical Bacteriology","subjectScheme":"FOR"},{"subject":"110199 Medical Biochemistry and Metabolomics not elsewhere classified","subjectScheme":"FOR"},{"subject":"110802 Medical Infection Agents (incl. Prions)","subjectScheme":"FOR"},{"subject":"111715 Pacific Peoples Health","subjectScheme":"FOR"},{"subject":"111403 Paediatrics","subjectScheme":"FOR"},{"subject":"Pathogenesis"},{"subject":"111504 Pharmaceutical Sciences","subjectScheme":"FOR"},{"subject":"111505 Pharmacogenomics","subjectScheme":"FOR"},{"subject":"FOS: Medical biotechnology","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Medical biotechnology","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified","subjectScheme":"FOR"},{"subject":"111716 Preventive Medicine","subjectScheme":"FOR"},{"subject":"111717 Primary Health Care","subjectScheme":"FOR"},{"subject":"110203 Respiratory Diseases","subjectScheme":"FOR"},{"subject":"111506 Toxicology (incl. Clinical Toxicology)","subjectScheme":"FOR"},{"subject":"110404 Traditional Chinese Medicine and Treatments","subjectScheme":"FOR"}],"contributors":[],"dates":[{"date":"2016-05-15","dateType":"Created"},{"date":"2016-05-15","dateType":"Updated"},{"date":"2016","dateType":"Issued"}],"language":null,"types":{"ris":"DATA","bibtex":"misc","citeproc":"dataset","schemaOrg":"Dataset","resourceType":"Dataset","resourceTypeGeneral":"Dataset"},"relatedIdentifiers":[],"relatedItems":[],"sizes":["105041 Bytes"],"formats":[],"version":null,"rightsList":[{"rights":"Creative Commons Attribution 4.0 International","rightsUri":"https://creativecommons.org/licenses/by/4.0/legalcode","schemeUri":"https://spdx.org/licenses/","rightsIdentifier":"cc-by-4.0","rightsIdentifierScheme":"SPDX"}],"descriptions":[{"description":"Doxofylline is chemically designated as 7-(1, 3 dioxolone-2-yl methyl) theophylline. Presence of a dioxolane group inposition C-7 differentiates it from theophylline. It is a new antibronchospastic drug recently introduced in therapy withpharmacological properties like theophylline; a potent adenosine receptor antagonist. doxofylline do not affect gastric acid secretion; either invivo or in-vitro; unlike theophylline. The lack of side effects with doxofylline indicates that the drug can be used safely and effectively. Some analytical methods for quantitative determination of doxofylline in pharmaceutical formulations like UV-Spectrophotometry, HPLC and LC-MS are reported. The present review deals with the various analytical methods reported as well as adopted for the estimation of doxofylline.CONCLUSION:Doxofylline is available and frequently used in market;hence, there is great need to determine it in bulk, dosageform as well as to estabilish pharmacokinetic parameters.The need of analytical method validation is well reflect andhighlights the aspect of analyst’s personal habits, that frompart of the developed methods, and on the possibility of aperson getting very reproducible results when he carries outthe analysis again and again in a similar set of conditions.Any developed method however, may be influenced byvariable like different elapsed assay times, different days,reagent lots, instruments, equipments or apparatus,environmental condition like temperature etc.","descriptionType":"Abstract"}],"geoLocations":[],"fundingReferences":[],"xml":"<?xml version="1.0" encoding="UTF-8"?>
<resource xmlns="http://datacite.org/schema/kernel-4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.6084/M9.FIGSHARE.3381292</identifier>
  <creators>
    <creator>
      <creatorName>Akhilesh  Gupta</creatorName>
    </creator>
  </creators>
  <titles>
    <title>An analytical approach of doxofylline: review</title>
  </titles>
  <descriptions>
    <description descriptionType="Abstract">&lt;div&gt;Doxofylline is chemically designated as 7-(1, 3 dioxolone-2-yl methyl) theophylline. Presence of a dioxolane group in&lt;/div&gt;&lt;div&gt;position C-7 differentiates it from theophylline. It is a new antibronchospastic drug recently introduced in therapy with&lt;/div&gt;&lt;div&gt;pharmacological properties like theophylline; a potent adenosine receptor antagonist. doxofylline do not affect gastric acid secretion; either invivo or in-vitro; unlike theophylline. The lack of side effects with doxofylline indicates that the drug can be used safely and effectively. Some analytical methods for quantitative determination of doxofylline in pharmaceutical formulations like UV-Spectrophotometry, HPLC and LC-MS are reported. The present review deals with the various analytical methods reported as well as adopted for the estimation of doxofylline.&lt;/div&gt;&lt;div&gt;&lt;div&gt;CONCLUSION:&lt;/div&gt;&lt;div&gt;Doxofylline is available and frequently used in market;&lt;/div&gt;&lt;div&gt;hence, there is great need to determine it in bulk, dosage&lt;/div&gt;&lt;div&gt;form as well as to estabilish pharmacokinetic parameters.&lt;/div&gt;&lt;div&gt;The need of analytical method validation is well reflect and&lt;/div&gt;&lt;div&gt;highlights the aspect of analyst’s personal habits, that from&lt;/div&gt;&lt;div&gt;part of the developed methods, and on the possibility of a&lt;/div&gt;&lt;div&gt;person getting very reproducible results when he carries out&lt;/div&gt;&lt;div&gt;the analysis again and again in a similar set of conditions.&lt;/div&gt;&lt;div&gt;Any developed method however, may be influenced by&lt;/div&gt;&lt;div&gt;variable like different elapsed assay times, different days,&lt;/div&gt;&lt;div&gt;reagent lots, instruments, equipments or apparatus,&lt;/div&gt;&lt;div&gt;environmental condition like temperature etc.&lt;/div&gt;&lt;/div&gt;</description>
  </descriptions>
  <subjects>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">60101 Analytical Biochemistry</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">30199 Analytical Chemistry not elsewhere classified</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">30101 Analytical Spectrometry</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110701 Allergy</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111501 Basic Pharmacology</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111205 Chemotherapy</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111101 Clinical and Sports Nutrition</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110302 Clinical Chemistry (diagnostics)</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110303 Clinical Microbiology</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111002 Clinical Nursing: Primary (Preventative)</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111003 Clinical Nursing: Secondary (Acute Care)</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111004 Clinical Nursing: Tertiary (Rehabilitative)</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111502 Clinical Pharmacology and Therapeutics</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111503 Clinical Pharmacy and Pharmacy Practice</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110399 Clinical Sciences not elsewhere classified</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111704 Community Child Health</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110305 Emergency Medicine</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111705 Environmental and Occupational Health and Safety</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111706 Epidemiology</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111707 Family Care</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111708 Health and Community Services</subject>
    <subject>Health Care</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111709 Health Care Administration</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111710 Health Counselling</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111711 Health Information Systems (incl. Surveillance)</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111712 Health Promotion</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111602 Human Biophysics</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110699 Human Movement and Sports Science not elsewhere classified</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110310 Intensive Care</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">119999 Medical and Health Sciences not elsewhere classified</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110801 Medical Bacteriology</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110199 Medical Biochemistry and Metabolomics not elsewhere classified</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110802 Medical Infection Agents (incl. Prions)</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111715 Pacific Peoples Health</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111403 Paediatrics</subject>
    <subject>Pathogenesis</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111504 Pharmaceutical Sciences</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111505 Pharmacogenomics</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111716 Preventive Medicine</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111717 Primary Health Care</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110203 Respiratory Diseases</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111506 Toxicology (incl. Clinical Toxicology)</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110404 Traditional Chinese Medicine and Treatments</subject>
  </subjects>
  <publisher>figshare</publisher>
  <publicationYear>2016</publicationYear>
  <dates>
    <date dateType="Created">2016-05-15</date>
    <date dateType="Updated">2016-05-15</date>
  </dates>
  <resourceType resourceTypeGeneral="Dataset">Dataset</resourceType>
  <sizes>
    <size>105041 Bytes</size>
  </sizes>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</rights>
  </rightsList>
</resource>","url":"https://figshare.com/articles/dataset/An_analytical_approach_of_doxofylline_review/3381292","contentUrl":null,"metadataVersion":3,"schemaVersion":"http://datacite.org/schema/kernel-4","source":"mds","isActive":true,"state":"findable","reason":null,"viewCount":0,"viewsOverTime":[],"downloadCount":0,"downloadsOverTime":[],"referenceCount":0,"citationCount":0,"citationsOverTime":[],"partCount":0,"partOfCount":0,"versionCount":0,"versionOfCount":0,"created":"2016-05-15T06:18:08.000Z","registered":"2016-05-15T06:18:09.000Z","published":"2016","updated":"2020-09-04T11:03:38.000Z"},"relationships":{"client":{"data":{"id":"figshare.ars","type":"clients"}},"provider":{"data":{"id":"otjm","type":"providers"}},"media":{"data":{"id":"10.6084/m9.figshare.3381292","type":"media"}},"references":{"data":[]},"citations":{"data":[]},"parts":{"data":[]},"partOf":{"data":[]},"versions":{"data":[]},"versionOf":{"data":[]}}}}